CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation is scheduled for January 11 at 6:00 AM ET, with a webcast available on demand afterward. CNS Pharmaceuticals focuses on innovative treatments for brain and central nervous system cancers, particularly its lead drug candidate, Berubicin, which targets glioblastoma multiforme. A Phase 2 trial for Berubicin is expected to begin in the U.S. by the end of Q1 2021.

HOUSTON, Jan. 7, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.

H.C. Wainwright BioConnect 2021 Conference:

Date:   Monday, January 11^th, 2021
Time: 6:00 AM ET
Link:   https://journey.ct.events/view/5dc204bc-7b68-4545-89b4-08ea81a4eee0

The webcast will be available on demand starting Monday, January 11^th, 2021 at 6:00 AM ET. Replays of the presentation will be available on the Company's website for 90 days following the event.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of the first quarter of 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, please visit www.CNSPharma.com.

View original content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-bioconnect-2021-conference-301202484.html

SOURCE CNS Pharmaceuticals, Inc.

FAQ

When will CNS Pharmaceuticals present at the H.C. Wainwright BioConnect 2021 Conference?

CNS Pharmaceuticals will present on January 11, 2021, at 6:00 AM ET.

What is the significance of Berubicin in CNS Pharmaceuticals' drug pipeline?

Berubicin is CNS Pharmaceuticals' lead candidate aimed at treating glioblastoma multiforme, an aggressive brain cancer.

What are the Phase 1 trial results for Berubicin?

The Phase 1 trial showed a 44% disease control rate, with one patient achieving a durable complete response.

When does CNS Pharmaceuticals expect to start the Phase 2 trial for Berubicin in the U.S.?

CNS Pharmaceuticals expects to commence the Phase 2 trial by the end of the first quarter of 2021.

What other drug candidate is CNS Pharmaceuticals developing?

CNS Pharmaceuticals is also developing WP1244, a DNA binding agent shown to be 500 times more potent than daunorubicin in preclinical studies.